Abstract
The present study was conducted in order to investigate the pharmacological activities of three heterobimetallic coordination compounds: [Cd(N-bishydeten)(2)][Ni(CN)(4)] (C1), [Cu(2)(N-bishydeten)(2)Co(CN)(6)].3H(2)O (C2), and K[Cd(N-bishydeten)Co(CN)(6)].1.5H(2)O (C3) (N-bishydeten = N,N-bis(2-hydroxyethyl)-ethylenediamine). This paper describes the ability of complexes to inhibit cell growth, cell migration and human topoisomerase I and to interact with DNA/BSA; this paper also evaluates the potential mechanisms of action exhibited by these compounds via the use of powerful measurement techniques. Studies on HT29, HeLa, C6 and Vero cells revealed that each compound demonstrated significant antiproliferative activity in conjunction with regressed cell migration velocity and caused apoptotic changes in morphology. There are strong data suggesting that the mechanisms of action exhibited by these compounds are associated with their DNA/BSA binding features. The IC(50) and binding constant range for the compounds are 20-180 µM and 1.2-3.2 x 10(4) M(-1), respectively. Moreover, we observed that these compounds alter the P53-Bcl-2 ratio and inhibit the relaxation activity of human topoisomerase I. Furthermore, a correlation between the antiproliferative effects of these compounds and their cytotoxic activity was observed. In conclusion, preliminary information demonstrates that these compounds have been found to exhibit effective antiproliferative activity against cancer cell lines, indicating that they are a potent candidate for further pharmacological study.